09 Jan 2015 Posted in ABPI statement By Press Office
Paul Catchpole said:
“We deplore any decision to restrict or remove patient access to cancer medicines. We reiterate that we are very disappointed that NHS England did not address concerns about the flawed process they are following, raised by the ABPI and pharmaceutical companies, before proceeding to re-evaluate CDF medicines. Such a re-evaluation process would not be necessary if NICE quickly evolves the way it evaluates cancer medicines as part of more fundamental reforms.
“The NHS England mechanism for evaluating medicines is crude and there is a risk that by evaluating cancer medicines in this manner important costs and benefits will be missed out of the process, potentially resulting at best in misleading conclusions being drawn and at worst NHS patients being denied access to CDF medicines which do provide significant health benefit. The ABPI does not support such an approach; any further development of a value assessment process for CDF medicines should be undertaken by NICE. We urgently need a clear plan with a set of agreed timelines setting out how a sustainable solution will be achieved”.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811